WINDSOR, England, May 11, 2017 /PRNewswire/ --
Dr Joanne Bedwell-Garner joins management team
MacrophagePharma Limited ('MPL') the immuno-oncology development company, announced today that it has appointed Dr Joanne Bedwell-Garner as Development Director. Dr Bedwell-Garner will be responsible for advancing the clinical development of Macrophage Pharma's
Dr Bedwell-Garner brings over 25 years' experience in the pharmaceutical sector, having held numerous senior Research and Development roles at companies including BTG, where she was Vice President of Non-Clinical Development and was responsible for non-clinical evaluation and translation into the clinic. Prior to this she held senior roles at Protherics, Emergent BioSolutions and Microscience. Dr Bedwell-Garner has a successful track record in taking greater than 15 pre-clinical candidates into clinical development; particularly in the areas of oncology, inflammation, cardiovascular and infectious disease. She obtained a PhD in oncology from University of London.
Dr Joanne Bedwell-Garner, newly appointed Development Director, added: "I am excited to join Macrophage Pharma's highly experienced team to maximise the full therapeutic potential of the ESM technology in immuno-oncology."
Macrophage Pharma's ESM technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner, activating the body's natural immune system to fight cancer. The platform has the ability to provide next-generation immunotherapies for a number of different cancers.
The Company's lead p38MAPi programme is focused on a novel macrophage-targeting p38 MAPK inhibitor. Clinical trials are scheduled to start in 2018. The Company is also developing discovery stage programmes centred on a number of proprietary, candidate compounds.
Macrophage Pharm will be presenting at Bio€quity Europe 2017 on Monday 22nd May at 4.20pm in the Next Wave company session.
About Macrophage Pharma Limited
Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses.
Its proprietary Esterase Motif Technology (ESM) platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner, activating the body's natural immune system to fight cancer. The platform has the ability to provide next-generation immunotherapies for a number of different cancers.
Founded by the CRT Pioneer Fund (CPF), the Company recently raised £9 million in a Series A financing round, led by CPF and two new specialist investors, Novo A/S and Aglaia Biomedical Ventures BV.
Macrophage Pharma's strategy is to complete the preclinical development of its lead development candidate, a p38 MAP kinase inhibitor, and advance two additional discovery candidates into pre-clinical development.
The company's management team, led by Dr Steven Powell, Chief Executive Officer, has a track record of success in the pharma industry ranging from early discovery to commercialisation. The Scientific Advisory Board is comprised of world-leading immunologists and cancer researchers who will help shape the future development of the company's unique approach in immuno-oncology.
For more information, please visit the company website: www.macrophagepharma.com
Media Contact: Macrophage Pharma Steven Powell, Chief Executive Officer Email: firstname.lastname@example.org
Hollie Vile Email: email@example.com Tel: +44-(0)-7729-362-590
SOURCE Macrophage Pharma Limited
Subscribe to our Free Newsletters!
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...
Unintended pregnancies are very common these days, and so one in about four pregnant women go for ...
Dizziness is a feeling of being faint or unsteady whereas Vertigo is a feeling that you or your ...View All